Finanzen von Translational Development Acquisition Corp (TDAC)TDACTranslational Development Acquisition Corp

Evaluating the bottom line, Translational Development Acquisition Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of 3.58%, provide a clear picture of how effectively TDAC converts its operational activities into shareholder value.

In the context of the broader market, TDAC competes directly with industry leaders such as HAVA and IDAC. With a market capitalization of $209.31M, it holds a significant position in the sector. When comparing efficiency, TDAC's gross margin of N/A stands against HAVA's N/A and IDAC's N/A. Such benchmarking helps identify whether Translational Development Acquisition Corp is trading at a premium or discount relative to its financial performance.

TDAC has shown fluctuations in net income, with a significant loss of -61283.00 USD in Q3 2024, but has seen improvements in subsequent quarters, including a net income of 6362427.00 USD in Q4 2025. However, the forward P/E ratio is currently 0, indicating uncertainty in future earnings.